This Biotech Reprogrammes Our Own Cells To Heal The Body
- 2 months ago
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. was recently a guest on Benzinga's All-Access.
Enlivex is a clinical-stage biotechnology company focused on macrophage reprogramming that intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis and other indications.
The company's therapy, AllocetraTM, is being tested as a cure for sepsis, one of the biggest unmet needs in healthcare. Sepsis is the third leading cause of death in hospitals today.
Enlivex is a clinical-stage biotechnology company focused on macrophage reprogramming that intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis and other indications.
The company's therapy, AllocetraTM, is being tested as a cure for sepsis, one of the biggest unmet needs in healthcare. Sepsis is the third leading cause of death in hospitals today.